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Antipsychotics used in the treatment of schizophrenia are known to cause weight gain. Phytoconstituents are used to 
manage such drug-induced weight gain. Ursolic acid is a pentacyclic triterpenoid commonly present in many herbs and 
fruits which are used in daily life. The effect of ursolic acid on antipsychotic-induced weight gain is not clear. Here, we 
investigated the effect of ursolic acid on olanzapine-induced weight gain in rats. Sprague-Dawley (SD) rats were divided 
into six different groups viz., normal control, olanzapine control, betahistine (10 mg/kg), and ursolic acid 10, 20 and 
40 mg/kg treated groups. All the drugs were administered once daily for 28 days orally. Except for the normal control group, 
all other animals were treated with olanzapine 4 mg/kg intraperitoneally to induce weight gain. During the experiment, 
animal’s behaviour variations were monitored at regular intervals. At the end of the experiment, blood sample was collected 
from all the experimental animals for biochemical analysis. Part of the brain, liver, heart, lung and kidney tissues were 
excised from the sacrificed animals and preserved in neutral formalin for histopathological studies. Ursolic acid showed a 
significant reduction in olanzapine-induced body weight gain on the rats. Increase in locomotor activity was also observed 
with the treatment of ursolic acid. Compared to ursolic acid, betahistine showed better tolerance against olanzapine-induced 
body weight gain. 
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Antipsychotics are major tranquilizers used in the 
treatment of schizophrenia, bipolar disorder, 
dementia, unipolar depression, obsessive-compulsive 
disorder, etc
1
. The adverse effects of antipsychotics 
include impaired memory, extrapyramidal effects, 
weight gain and metabolic dysfunction
2
. Weight gain 
is often the most common and visible side effect of 
atypical antipsychotic agents and it causes serious 
health risks
3
. The atypical antipsychotics such as 
clozapine and olanzapine have the most weight 
gaining potential when compared with other 
antipsychotic agents
4
. Olanzapine is a 
thienobenzodiazepine and acts as antagonist at 5HT2A 
and D2 receptor
5
. While the corticostriatal pathways
are responsible for therapeutic action of olanazepine, 
the actions on nigrostriatal pathway, and 
antihistaminic and antiserotonergic properties 




Many of the plant 
phytoconstituents including ursolic acid found to have 
preventive effect against drug-induced weight gain. 
Ursolic Acid is a pentacyclic triterpenoid, widely 
distributed in herbs
7
. In many studies, ursolic acid 
showed a beneficial effect against diet or drug-
induced weight gain
8-10
. Ursolic acid has significant 
nitration with muscarinic, dopaminergic, peroxisome 
proliferator-activated receptor (PPAR)-α and, etc. 
receptor sites
11,12
. Earlier studies have reported that 
PPAR-α agonist reverses the increased levels of 
triglycerides and insulin resistance caused by 





It is reported that ursolic acid also has 
the ability to increase protein kinase B (Akt) activity 
in muscles that involve in multiple cellular processes 
such as cell apoptosis, cell proliferation, cell 
migration, transcription, glucose metabolism, and 
increased fat burning. Akt, specifically located in 
skeletal muscles which elevate the energy 
expenditure, reduces adiposity and blood glucose and 
impart resistance to glucose intolerance, diet-induced 




The effect of 
ursolic acid on atypical antipsychotic agent-induced 
weight gain remains unclear. Hence, in the present 
study, we explored the effect of ursolic acid on 
olanzapine-induced weight gain and associated 
—————— 
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metabolic and behavioural variations and compared it 
with betahistine, a known inhibitor of antipsychotic-
induced weight gain, related metabolic and 
behavioural variations. 
 
Materials and Methods 
Chemicals 
Ursolic acid and olanzapine were purchased from 
Sigma-Aldrich, USA. Betahistine Dihydrochloride 
(Betaserc®) was purchased from a retail pharmacy. 
Ursolic acid was suspended with 0.05% w/v of 
carboxymethyl cellulose (CMC). Olanzapine was 
dissolved in 0.1 N hydrochloric acid and pH was 
adjusted to ~5.5 (using 0.1 N NaOH) and the final 





Healthy, adult, female Sprague-Dawley (SD) rats, 
weighing 150±10 g obtained from the Central Animal 
house, AIMST University, Malaysia were housed in 
large, spacious poly acrylic cages at ambient room 
temperature (22-25°C) with 12 h light/dark cycle and 
fed with water, and normal rats pellet diet ad libitum. 
Prior approval was obtained from AIMST  
University Human and Animal Ethics Committee 
(AUHAEC1/FOP/SP/2015) to carry out the study, and 
conducted according to University Animal Research 
Review Panel guidelines. 
 
Effect of ursolic acid on olanzapine-induced weight gain 
The rats were divided into six groups of six 
animals. Animals in group I was considered as normal 
control and they were treated with CMC. Group II 
animals were treated with olanzapine (4 mg/kg/day) 
and group III was treated with betahistine  
(10 mg/kg/day) along with olanzapine (4 mg/kg/day). 
Animals in group IV to VI were treated with ursolic 
acid 10, 20 and 40 mg/kg/day, respectively, along 





administered intraperitoneally and ursolic acid was 
administered orally every day for 28 days.  
During the study, body weight changes, food and 
water intake variations and, behavioural alterations 
were monitored at regular intervals. At the end of the 
study, animals were mildly anesthetized with diethyl 
ether and one ml of blood was collected for 
biochemical analysis, then they were sacrificed by 
cervical dislocation. The brain, lung, heart, liver, 
kidney, reproductive organs and peritoneal adipose 
tissues were collected and absolute organ weight was 
measured. The body weight of each rat in each group 
was recorded at regular intervals.  
Daily food and water intake was measured in each 
group and compared with that of control. 
 
Behavioural analysis 
The locomotor activity, anxiety levels, learning and 
memory activities, and grip strength were evaluated at 
regular intervals.  
 
Locomotor activity 
The mobility of rats were recorded in a rodent 
activity cage (actophotometer [manufactured by 
Jainsons (India) Regd. Haryana, India]) equipped with 
acrylic cage and six built-in photo sensor and digital 
counters beams on both x and y horizontal axis. The 
activity of the individual rat was monitored at room 
temperature for 5 min. 
 
Learning and memory (water maze test) 
Water navigation test was employed to assess 
learning and memory parameters and, escape latency 
time (ELT) to evaluate the spatial learning and 
memory functions. The water maze consists of 
circular tank with 90 cm diameter and wall 20 cm 
above the water level with 25°C water. A square 
platform (10×5 cm) is hidden 2 cm below the water 
level. Training had been taken place for 3 consecutive 
days, with a 4 consecutive trials/day for each 
experimental rat at the inter-trial interval of 30 min. 
The tank was divided into 4 equal quadrants and trail 
was started from one of four assigned polar positions 
with different sequence each day. The latency was 
measured by observing the time to reach the platform 
by the animal. Any animal fails to reach the platform 





Anxiogenic effects (elevated plus maze) 
The rodent elevated plus maze consists of two open 
arms and two enclosed arms with the dimension of 
50×10×60 (L-W-H) cm. Two open and enclosed arms 
are opposite to each other and maze is elevated to a 





day of the experiment, the rat was placed in 
the center of the maze, facing one of the enclosed 
arms and monitored for 10 min. The number of 
entries to each arm and time spent in each arm were 





Wire grip strength 
This test employed to assess the skeletal muscle 
function in rodents. The apparatus consisted of a 
metallic wire (90 cm length, 4 mm in diameter), fixed 
horizontally between two retort stands and 60 cm 




The rats were forced to hold 




the middle of the wire. Training was conducted for 
three consecutive days. Control rats as well as 
olanzapine administered rats were observed for the 
duration taken by rats to support their weight holding 
on the metal string attached. Each rat was subjected to 
5 trials with at least 10 min rest period in between 
tests
20
. The latency to fall from the wire was noted.  
 
Biochemical parameters 
At the end of the study, one ml of the blood was 
collected from all the animals through retro-orbital 
sinus puncture by using a plain glass tube. The serum 
was separated by centrifugation at 3000 RPM for  
20 min at 4°C, and stored at −80°C until further 
biochemical analysis.  
The serum levels of alkaline Phosphatase (ALP), 
glucose, aspartate transaminase (AST), alanine 
transaminase (ALT), total protein, urea, creatinine, 
total cholesterol (TC), triglyceride (TG), and high 
density lipoprotein-cholesterol (HDL) were analyzed 
using biochemical analyzer (Reflotron Plus System, 
Hoffmann-La Roche, USA). The Non-HDL, LDL, 
HDL ratio, VLDL and Atherogenic dyslipidemia 
[AD] were calculated using following formula TC-
HDL; TC/1.19 + TG/1.9 – HDL/1.1 – 38; [HDL-






Part of the liver and kidney samples from normal 
control, olanzapine control, betahistine and ursolic 
acid 40 mg/kg groups were preserved in 10% neutral 
formalin for histopathological analysis. The brain, 
liver, and kidney tissue was embedded in paraffin 
after being dehydrated in alcohol and subsequently 
cleared with xylene. Paraffin-embedded tissue blocks 
were prepared and five-micrometer thickness of 
section was taken with Microtome (Thermo Electron 
Corporation, England) for routine histopathology. 
Briefly, the sections for histopathology was placed on 
an albuminized glass slide, deparaffinized, rehydrated 
and stained with routine hematoxylin and eosin 
(H&E). After mounting with DPX and coverslip the 
slides were examined under a light microscope and 
reporting was done. 
 
Statistical analysis 
The mean ± standard error of the mean (n = 6) 
values was calculated for each group except group III 
and IV (n = 5). It was found that one animal from 
Group III and IV were dead on the 6
th
 day of the 
experiment. Statistical differences among the groups 
were determined using One-way ANOVA followed 




Effect of ursolic acid on food and water intake 
The group treated with olanzapine and olanzapine 
+ ursolic acid 10 mg showed a significant increase in 
food intake while the group treated with olanzapine + 
ursolic acid 40 mg did not show any significant 
alteration in regular food intake when compared to 
control. Rats treated with olanzapine and olanzapine + 
ursolic acid 10 mg showed a significant increase in 
food intake from 14
th
day onwards when compared 
with that of control. The effect of ursolic acid on 
olanzapine-induced changes in food intake of rats is 
summarized in Fig. 1. Significant changes in regular 
water intake were not observed with any of the treated 
group when compared to control. 
 
Effect of ursolic acid on olanzapine-induced weight gain  
The animals treated with olanzapine alone were 
found to have significant weight gain. The animals 
treated with olanzapine plus ursolic acid 10 mg/kg a 
showed significant increase in body weight compared 
to other groups. While the rats treated with olanzapine 
+ ursolic acid 40 mg showed a significant decrease in 
olanzapine-induced weight gain when compared to 
olanzapine control. The rats treated with olanzapine + 
betahistine showed no significant increase in body 
weight. The effect of ursolic acid on olanzapine-




Fig. 1 — Effect of ursolic acid on olanzapine-induced changes in 
food intake. [All the values are mean ± SEM (n=6, except 
olanzapine + betahistine [n=5] and olanzapine + ursolic acid  
10 mg [n=5] treated group). dP <0.05; eP <0.01 and fP <0.001 
compare to 1-7th day. (One-way ANOVA followed by Tukey 
post-hoc test). SEM: Standard error of the mean]. 




Effect of ursolic acid on Behaviour  
 
Effect of ursolic acid on locomotion 
Locomotion is considered as one of the indices for 
mental alertness. The rats treated with olanzapine 
showed a decrease in locomotor activity by 11.16% 
on the 14
th
 day and 88.17% on the 28
th
 day when 
compared to initial values. The rats treated with 
ursolic acid 20 and 40 mg/kg showed significant 
dose-dependent increases in locomotor activity 
throughout the study when compared to the 
olanzapine treated group. The effect of ursolic acid on 
motor coordination on rats is summarized in Table 2. 
Throughout the study, betahistine administered 
animals did not show any alteration when compared 
to the pre-study locomotor activities.  
 
Effect of ursolic acid on Escape latency time 
Effect of ursolic acid on water navigation of rats is 
summarized in Table 2. In post training, ursolic acid 
treated animals showed decreased ELT compared 
with that of control.  
 
Effect of ursolic acid on grip strength 
Throughout the study, the rats treated with 
olanzapine showed a decrease in their grip strength 
(25.61% on the 14
th
 day and 4.08% on the 28
th
 
day). The rats treated with betahistine showed a 
significant increase in their grip strength. The rats 
treated with ursolic acid also showed an increase  
in grip strength, but the values are not significant.  
The effect of ursolic acid on olanzapine on grip 
strength of rats is shown in Table 2.  
 
Anxiogenic effects ursolic acid 
The normal control animals did not show any 
alterations in behaviour whereas betahistine and 
ursolic acid treated animals showed significant 
alterations in anxiogenic behaviour (Fig. 2). The rats 
administered with olanzapine showed an increased 
number of entries in dark arm and the rats treated with 
betahistine showed increased time spent in dark 
compared with that of pre-study values. The rats 
treated with ursolic acid showed decreased duration of 
stay and number of entries in dark. 
 
Effect of ursolic acid on absolute and relative organ weights 
Effects of ursolic acid on absolute and relative 
organ weight of experimental rats were summarized 
in Table 3. The rats treated with olanzapine showed a 
significant increase in the absolute organ weight of 
brain, kidney, and uterus when compared to control. 
Betahistine and ursolic acid 10 mg/kg treated animals 
showed a significant increase in lung weight when 
compared to control. Olanzapine treated animals 
showed a significant increase of relative uterus weight 
when compared to control. Betahistine and ursolic 
acid 10 mg/kg treated animals showed a significant 
increase in lung’s weight when compared to the 
olanzapine treated group.  
Table 1 — Effect of ursolic acid on olanzapine-induced body weight gain of rats 
Treatment 
Body weight (g) % changes (at 
the end of study) Pre-study day 7th day 14th day 21st day 28th day 
Control  152.50±3.74 153.50±4.06 156.67±3.29 158.83±2.39 162.67±2.40 6.87±2.06 
Olanzapine control 149.33±3.99 154.17±3.85 165.00±4.07 168.33±4.18 179.17±3.31# 20.13±1.40 
Olanzapine + Betahistine 150.20±3.32 152.80±2.37 154.80±2.59 155.80±2.71 157.00±1.87*** 4.66±1.41 
Olanzapine + Ursolic acid 10 mg 149.00±2.58 152.40±3.20 156.60±2.59 159.80±2.47 166.40±2.30* 11.71±0.62 
Olanzapine + Ursolic acid 20 mg 149.17±2.41 149.33±1.50 151.67±1.63* 152.33±2.01** 158.00±1.77*** 5.99±1.09 
Olanzapine + Ursolic acid 40 mg 148.83±2.81 150.17±3.16 149.67±3.13* 149.50±2.95*** 149.17±2.74*** 0.25±0.88 
[All the values are mean ± SEM (n=6, except olanzapine + betahistine [n=5] and olanzapine + ursolic acid 10 mg [n=5] treated group). *P 
<0.05, **P <0.05, ***P <0.05 compare to olanzepine treated group; #P <0.05 compare to control group (One-way ANOVA followed by 
Tukey post-hoc test). SEM: Standard error of the mean, SD: Sprague-Dawley] 
 
Table 2 — Effect of ursolic acid on locomotor activity, escape latency time and grip strength of rats 
Treatment 














Control  106.67±10.21 93.67±28.21 101.50±11.11 47.17±5.26 48.00±4.68 43.67±3.06 26.00±3.43 27.50±2.73 28.83±4.10 
Olanzapine control 101.50±24.30 90.17±22.58 10.67±2.81
#
 44.67±9.66 31.67±8.58 25.50±8.95
@
 27.33±7.70 20.33±5.28 19.50±5.83 






















20 mg 101.17±11.29 73.83±14.42 101.50±11.11 44.00±8.99 36.33±7.84 29.67±6.22 31.00±4.32 36.17±7.36 45.83±7.87 
40 mg 106.33±8.39 97.33±14.90 154.00±16.68** 44.83±8.90 30.83±7.89 23.00±4.41 28.83±6.85 41.00±6.94 48.17±6.12 
[All the values are mean ± SEM (n=6, except olanzapine + betahistine [n=5] and olanzapine + ursolic acid 10 mg [n=5] treated group). *P <0.05; 
**P <0.001 compare to olanzepine treated group; 
#
P <0.001 compare to control group (One-way ANOVA followed by Tukey post-hoc test).
 
@
Value of two animals (Only two animals reached platform, remaining animals failed to reach platform). SEM: Standard error of the mean] 
 




Effects of ursolic acid on serum biochemical parameters  
The animals treated with olanzapine showed 
significantly increased levels of serum glucose and 
creatinine when compared with that of the control 
group. Animals treated with betahistine and ursolic 
acid showed prevention of olanzapine-induced raise 
in serum glucose (Fig. 3A) and creatinine (Fig. 3B) 
levels. Olanzapine significantly increased the levels of 
triglycerides, LDL, VLDL and AD compared to that 
of control, whereas betahistine and ursolic acid 
prevented the olanzapine-induced raise in these 
parameters. Effect of ursolic acid on serum 
biochemical parameters and lipids profile are 
summarized in Figs 3 and 4. 
 
Effects of ursolic acid on histology of organs  
Histopathological findings are presented in Table 4 
and Fig. 5. Olanzapine treated animals showed 
mononuclear infiltration, dilated alveoli and vascular 
congestion in lungs (Fig. 5 A-C) whereas normal 
features and mild lymphocyte infiltration were 
observed with betahistine (Fig. 6A) and ursolic acid 
(40 mg/kg) treated animals, respectively. Fatty changes 
and degeneration of hepatocytes  in the  liver,  cardiac  
 
 
Fig. 2 — Effect of ursolic acid on anxiety (elevated plus maze) of rats. [All the values are mean ± SEM (n=6, except olanzapine + 
betahistine [n=5] and olanzapine + ursolic acid 10 mg [n=5] treated group). dP <0.05; eP <0.01 and fP <0.001 compare with that of pre-
study values (One-way ANOVA followed by Tukey post-hoc test).SEM: Standard error of the mean]. 
 
Table 3 — Effect of ursolic acid on (A) absolute; and (B) relative organ weight of rats 
Treatment 
Absolute organ weight (g) 








Control  1.71±0.06 1.54±0.06 0.57±0.03 5.96±0.33 0.32±0.02 0.31±0.02 0.63±0.04 2.62±0.14 
Olanzapine control 2.01±0.08## 1.66±0.05 0.65±0.03 6.44±0.17 0.38±0.01# 0.37±0.01# 0.75±0.03# 1.83±0.15# 
Olanzapine+Betahistine 1.68±0.08** 1.24±0.09#*** 0.57±0.04 5.77±0.19 0.30±0.01** 0.29±0.01** 0.58±0.03** 1.94±0.14 
Olanzapine+Ursolic acid 10 mg 1.65±0.04** 1.12±0.06###*** 0.56±0.04 6.22±0.56 0.35±0.01 0.35±0.01 0.70±0.03 1.98±0.19 
Olanzapine+Ursolic acid 20 mg 1.52±0.04*** 1.42±0.03 0.53±0.02 5.13±0.10 0.30±0.01** 0.29±0.01** 0.59±0.02** 1.80±0.21# 
Olanzapine+Ursolic acid 40 mg 1.53±0.04*** 1.33±0.04** 0.57±0.07 5.57±0.36 0.30±0.01** 0.30±0.01** 0.59±0.02** 2.04±0.20 
 Relative organ weight (g) 
Control  1.05±0.03 0.94±0.03 0.35±0.01 3.65±0.16 0.20±0.01 0.19±0.01 0.39±0.02 1.61±0.10 
Olanzapine control 1.13±0.06 0.92±0.02 0.36±0.02 3.61±0.14 0.21±0.01 0.21±0.00 0.42±0.01 1.02±0.07* 
Olanzapine+Betahistine 1.07±0.04 0.79±0.06# 0.36±0.03 3.67±0.12 0.19±0.01 0.18±0.01 0.37±0.01 1.24±0.10 
Olanzapine+Ursolic acid 10 mg 0.99±0.03 0.67±0.03##** 0.34±0.02 3.73±0.31 0.21±0.01 0.21±0.01 0.42±0.01 1.20±0.12 
Olanzapine+Ursolic acid 20 mg 0.96±0.03 0.90±0.02 0.34±0.01 3.25±0.07 0.19±0.01 0.19±0.01 0.38±0.01 1.14±0.14 
Olanzapine+Ursolic acid 40 mg 1.03±0.03 0.89±0.03 0.38±0.05 3.73±0.21 0.20±0.00 0.20±0.00 0.40±0.01 1.37±0.13 
[All the values are mean ± SEM (n=6, except olanzapine + betahistine [n=5] and olanzapine + ursolic acid 10 mg [n=5] treated group). 
*P <0.01; **P <0.001 compared to olanzepine treated group; #P <0.05, ##P <0.01 and ###P <0.001 compared to control group (One=way 
ANOVA followed by Tukey post-hoc test). SEM: Standard error of the mean] 
 





congestion in heart and severe tubular cell degeneration 
in kidney were observed in olanzapine treated animals 
(Fig. 5 D-F) whereas betahistine and ursolic acid 
reversed these effects (Fig. 6 A & B) and Fig. 7. 
 
Discussion 
Ursolic acid at 20 and 40 mg/kg has significantly 
resisted the olanzapine-induced weight gain and its 
effect was comparable with that of betahistine. This 
suggests that ursolic acid inhibits  olanzapine-induced  
 
 
Fig. 3 — (A) Effects of ursolic acid on serum biochemical 
parameters of rats; and (B): Effects of ursolic acid on serum 
biochemical parameters of rats. [All the values are mean ± SEM 
(n=6, except olanzapine + betahistine [n=5] and olanzapine + 
ursolic acid 10 mg [n=5] treated group). aP <0.05 and bP <0.01 
compared to control group; and dP <0.05, eP <0.01 and fP <0.001 
compared to olanzepine treated group (One-way ANOVA 
followed by Tukey post-hoc test). AST: Aspartate 
aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline 




Fig. 4 — Effects of ursolic acid on plasma lipid profile of rats. [All the values are mean ± SEM (n=6, except olanzapine + betahistine 
[n=5] and olanzapine + ursolic acid 10 mg [n=5] treated group). dP <0.05; eP <0.01 compare to olanzepine treated group; aP <0.05 and  
bP <0.01 compare to control group (One-way ANOVA followed by Tukey post-hoc test)] TC: Cholesterol, TG: Triglycerides, HDL: 
High-density lipoprotein, LDL: Low-density lipoprotein, LDL: Low-density lipoprotein, AD: Atherogenicdyslipidemia, SEM: Standard 
error of the mean]. 
Table 4 — Effects of ursolic acid on histology of organs 
Treatment Organ Findings 
Control  
(normal) 








Mononuclear cell infiltration, dilated 
alveoli and vascular congestion.   
Heart Mild cardiac congestion 
Liver 
Mild degeneration of hepatocytes and 
fatty changes 
Kidney 
No changes in glomeruli and sever 





Brain, Lung Normal 
Heart 
No evidence of necrosis or 
myocardial toxin 
Liver Mild degeneration of hepatocytes 
Kidney 
No changes in glomeruli and mild 





Brain, Kidney Normal 
Lung Mild lymphocyte infiltration 
Heart No evidence of necrosis. 
Liver 
No evidence of degeneration of 
hepatocytes 
 





weight gain. In some of the previous studies, 
betahistine, an H1 agonistic or H3 antagonist showed a 
beneficial effect against antipsychotics-induced 
weight gain.  Lian  et al   reported  that  betahistine  at  
2.7 mg/kg (t.i.d.) showed significant weight reduction 
in the rats co-administered with olanzapine (1.0 mg/kg; 
t.i.d.) for 2 weeks
24
. In another study, betahistine 




In humans, betahistine showed a significant weight 
reduction when it was co-administered with 
olanzapine (10 mg/day) in first-episode schizophrenia 




These studies clearly showed 
 
 
Fig. 5 — Histological features of various organs of rat treated with olanzapine 4 mg/kg. Section from lung of olanzapine 4 mg/kg treated 
animals shows (A) dilated alveoli; (B) infiltration of mononuclear cell; (C) vascular congestion; (D) heart showing mild cardiac 





Fig. 6 — Histological features of various organs of rat treated 
with betahistine 10 mg/kg. (A) Section from kidney of betahistine 
treated animals showing mild tubular cell degeneration; and (B) 
liver showing mild degeneration of hepatocytes. H&E, 400X. 
 
 
Fig. 7 — Section from lungs of ursolic acid 40 mg/kg treated 
animals shows mild lymphocyte infiltration. H&E, 400X. 
 




that partial histamine agonist/antagonist has a 
beneficial effect on the reduction of olanzapine-
induced weight gain. The effect of ursolic acid on 
olanzapine-induced weight gain was compared with 
betahistine. 
A pilot study of ‘olanzapine-induced weight gain’ 
was carried out in both the genders of SD rats. In the 
pilot study, both gender of animals received  
1.0 mg/kg intraperitoneal injection of olanzapine for 
two weeks. At the end of the study, it was found that the 
male rats did not respond to olanzapine as they did 
not show any significant increase in regular food 
intake and olanzapine-induced weight gain when 
compared to control. Whereas female rats showed a 
significant increase in regular food intake and weight 
gain compared to control. Hence, further studies were 
carried out with female SD rats. Albaugh et al., also 
studied metabolic effects of olanzapine in rodents and 
found that A/J mice, C57B1/6J mice, and male SD 
rats are not suitable to mimic the human pathological 
conditions of olanzapine-induced metabolic alterations 
and weight gain. From there study it is exhibited that, 





In human also, it was suggested that 
olanzapine caused weight gain which is mediated by 




Interaction of olanzapine with monoaminergic 
receptors and the effect of olanzapine administration 
on the regulation of hypothalamic mechanisms lead to 
hyperphagia, weight gain, and metabolic changes
29
. 
The animals treated with olanzapine showed 
significant increases in regular food intake and an 
increase in body weight when compared to normal 
animals. No significant changes in water intake were 
observed during the study. Murashita et al., reported 
that, olanzapine increases appetite by stimulating 
secretion of ghrelin in ghrelinergic cells of 
gastrointestinal tract, which results in an increase in 
food intake and weight gain
30
. The food intake and 
olanzapine’s effect on body weight was effetely 
resisted by ursolic acid. This may be due to the 





Olanzapine increased water intake, but 
the values are not significant. Fell et al.
31
 found that 
olanzapine increases regular weight gain, food and 
water intake, abdominal fat significantly.
 
Ursolic acid 
inhibits olanzapine-induced weight gain by enhancing 
skeletal muscle insulin (IGF-I) signaling, activating 
Akt (reduces weight gain and elevate energy 




Olanzapine found to have increased animals’ body 
weight and reduced locomotion, immobilization time, 
grip strength and increased level of anxiety, lipids 
level and, glucose level whereas ursolic acid inhibits 
all these olanzapine-induced metabolic effects. This 
indicates ursolic acid has significant antianxiety, anti-
hyperlipidemic and anti-hyperglycemic effects. Liu  
et al.
32
 studied the effect of olanzapine on MK-801 
induced cognitive deficits and found that, the animals 
treated with olanzapine + MK-801 decreased locomotor 
activity in the first 10 min of the test (results are not 
statistically significant) and olanzapine rescued 
animals from MK-801 induced cognitive deficits. 
Reduction in locomotor activity effects of olanzapine 






 reported the hypolipidemic effect of 
ursolic acid (50 mg/kg) in rats and Wang et al.
35
 
demonstrated the hypolipidemic effect of ursolic acid 
(25 mg/kg) in rabbits.
 
In male rats, ursolic acid also 
showed anxiolytic effect and this effect was comparable 
to diazepam
36
. Betahistine showed anxiogenic effect but 
no effect on locomotion. Imaizumi et al.
37
 also reported 
the same, but in their study betahistine showed a 
significant reduction in locomotion and this effect may 
be mediated through H1 receptor.
 
Both ursolic acid and 
betahistine reduced the ELT, suggesting that short-term 
hippocampus-dependent spatial memory is improved
38
. 
Ursolic acid 40 mg/kg increased the muscular 
coordination and this may be due to inhibition of muscle 
breakdown via genetic signalling
15
. 
At the end of the study, olanzapine showed 
increased levels of glucose, liver enzymes and cellular 
metabolites/ nitrogenous end products and this was 
supported by histopathological reports. In absolute 
and relative weight of organs, betahistine showed a 
reduction in the weight of lungs and kidneys.  
The reason for weight reduction is unknown. 
Olanzapine is known to cause hyperglycaemia and 





The animal treated with ursolic acid 
also showed hepatoprotective effect and the same was 
reported by Shukla et al.
42
. Ursolic acid normalizes 
the bile flow in a dose-dependent manner and 
anticholestatic property as it increases the bile flow, 
bile acids, and bile salts, which possibly due to 




Olanzapine treated rats were observed to have 
increased in their aminotransferase (ALT, AST) level 




compared to other groups. Olanzapine has been 
reported to be causing the most transient, 
asymptomatic increase in hepatic enzyme among all 
these atypical antipsychotics. The pathogenesis of 
olanzapine-associated hepatotoxicity is still not well 





histopathology, olanzapine, betahistine, and ursolic 
acid-treated groups showed mild degeneration of 
hepatocytes and this may be due to olanzapine-
induced metabolic changes including dyslipidemia
45
. 
Rats treated with ursolic acid showed a reduction in 
aminotransferase level, maybe due to its antioxidant 
properties
46
. During the study, the animal administered 
with olanzapine + betahistine and olanzapine + ursolic 
acid 10 mg/kg (Gr. V) showed animal mortality and 
the reason for the death of an animal from each of 
these groups is not clear. But the olanzapine has two 
times higher risk on the incidence of sudden cardiac 






Chronic administration of olanzapine increased 
body weight and altered the metabolic pattern of 
experimental animals whereas ursolic acid at  
40 mg/kg significantly resisted the olanzapine-induced 
metabolic changes which include hyperglycemia, 
hyperlipidemia, and weight gain. These effects of 
ursolic acid at 40 mg/kg were comparable with that of 
betahistine 10 mg/kg. From the results, it is inferred 
that ursolic acid at 40 mg/kg inhibits olanzapine-
induced metabolic changes and, this effect may be 
due to its action on insulin signaling, protein kinase B, 
adiposity, blood glucose level and/or oxidative  
stress. 
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